A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
Clinical trial NCT00660621 · UNKNOWN
Trial details
- NCT number
- NCT00660621
- Sponsor
- Kentuckiana Cancer Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-04-01
- Primary completion
- 2010-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.